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Abstract: Background 
Studies have shown patient attitudes to be an important predictor for health related behaviours 
including medication adherence. It is less clear whether patient attitudes also predict medication 
adherence among patients with psychoses.   
Method 
We conducted a systematic review and meta analysis of the data of studies that tested the association 
of attitude measures with medication adherence among patients with psychoses.   
14 studies conducted between 1980 and 2010 were included.  
Results 
Results show a small to moderate mean weighted effect size (r+ = .25 and .26 for Pearson and  
Spearman correlations, respectively).  
Conclusions 
Theory based interventions that target potentially modifiable attitude components are needed to 
assess the relationship between positive patient attitudes and adherence behaviours among patients 
with psychoses. 
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Abstract 
 
Background 
Studies have shown patient attitudes to be an important predictor for health related 
behaviours including medication adherence. It is less clear whether patient attitudes also 
predict medication adherence among patients with psychoses.   
Method 
We conducted a systematic review and meta analysis of the data of studies that tested the 
association of attitude measures with medication adherence among patients with psychoses.   
14 studies conducted between 1980 and 2010 were included.  
Results 
 Results show a small to moderate mean weighted effect size (r
+
 = .25 and .26 for Pearson 
and  Spearman correlations, respectively).  
Conclusions 
Theory based interventions that target potentially modifiable attitude components are needed 
to assess the relationship between positive patient attitudes and adherence behaviours among 
patients with psychoses. 
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Do attitudes towards medication adherence predict medication adherence behaviours among 
patients with psychosis? a systematic review and meta analysis 
 
1. Introduction 
 
 
Failure to adhere to medication is an important issue among all disease groups, with 
costly implications both for the patient and health service providers.  Among patients with 
psychoses, non-adherence rates are particularly high, with reports ranging from 20% to 89% 
[1].  It has been proposed that patients with psychoses lack insight into their illness, and that 
this influences adherence to medication regimes [2].  Non-adherence to antipsychotic 
medication may not only enhance distressing symptoms, and the likelihood of relapse but 
negatively influence the patients‟ quality of life and long-term prognosis [3]. Moreover, 
failure to adhere to prescribed regimens may result in longer and more frequent periods of 
inpatient care, leading to increases in the overall cost of care [4].   
Accumulating evidence suggests that more positive patient attitudes towards 
medication adherence lead to better adherence behaviours  among various populations 
including patients with psychoses [5].  This observation coincides with  increasing emphasis 
that is placed on patient-reported outcomes (PROs)  among patients with psychoses [6] 
suggesting that  a focus on individual‟s cognitive representations may-be  relevant to clinical 
treatment outcomes among this patient population.  This perspective coincides with various 
social cognitive models (SCMs) such as the health belief model [7] and theory of planned 
behaviour [8] that assess various cognitive representations or beliefs about health 
behaviours.  While relatively few studies have utilised social cognitive theories among 
patients with psychoses [see 9,10 for exceptions] they have been applied successfully to 
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numerous health behaviours including adherence to medication regimes among patients with 
urinary tract infections [11], diabetes [12], HIV or AIDS [13] and travellers in malarias 
regions [14]. 
Among psychiatric populations, the self reported drug attitude inventory [DAI; 15], 
and the observer rating of medication influence [ROMI; 16] have been predominately 
utilised to assess patient attitudes towards adherence.   Like attitude constructs in the HBM 
[17] and the TPB [8] these measures assess beliefs about medication adherence including 
perceived benefits, costs, and relapse prevention   Additionally, the ROMI includes aspects 
of therapeutic alliance, normative beliefs, and barriers to treatment.  
Patient attitudes towards mediation adherence may provide a potentially important 
target for intervention as they are proposed to be potentially modifiable [8].  However, 
before  the relevance of attitudes for adherence among patients with psychoses can be 
established, research synthesis is needed to examine i) the size of the association between 
attitudes and medication adherence behaviours and ii) the  generalisability of the findings 
across the relevant studies. 
In this review we aim to assess the extent to which available evidence supports the 
development of behaviour change interventions that target patient attitudes by accumulating 
quantitatively the available evidence on the association between attitudes and medication 
adherence behaviours among patients with psychoses.  Specifically, systematic search and 
meta-analytic techniques were employed to test the hypotheses that positive patient attitudes 
towards medication will be positively correlated with adherence behaviours among patients 
with psychoses.  Additionally, study quality will be explored as a moderator of the 
attitude/adherence association. 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
2. Method 
2.1 Searches and inclusion criteria 
A three-stage systematic search was undertaken to locate primary research papers 
relevant to the review. Initial search terms contained adjectives or derivatives of the 
following 4 terms: “medication” (e.g., neuroleptic or antipsychotic), “compliance” (e.g., 
adherence), “attitudes” (e.g., subjective response or health beliefs) and “psychosis” (e.g.,  
schizophrenia or schizo or psychosis) that were combined using a series of Boolean and/or 
operators and wildcards. These combinations were used to search Medline, Psychinfo, and 
Psych-articles databases between 1980 and 2010. Only English language journals were 
considered.  
Potentially relevant articles were exported into a reference citation manager where 
titles and abstracts were screened for relevance.  At stage 2, studies were included only if a)  
at least 70% of the sample were diagnosed as having a psychotic disorder (including 
schizophrenia, schizo-affective disorder, and psychoses), b)  an established measure of 
attitude was included  c) attitude was linked bivariately to at least one measure of medication 
adherence.  The effect size r was used as it represents both the direction and strength of 
associations. Where data was missing, authors were contacted.  Papers from which data were 
extracted are marked with an asterisk in the reference section.  
2.2 Data coding 
 
The following data was coded from each primary article where present a) reference 
details; b) country; c) sample size and patient diagnoses; d) attitude measure(s); e) study 
design and length of time to outcome; f) adherence measure(s); g)  effect size estimate in r; 
h) internal  reliability of the attitude measure(s); i) internal reliability of the adherence 
measure(s).  Following previous research [18] Pearson and Spearman correlations were 
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analysed independently; the study details of which, are presented in tables 1 and 2, 
respectively. 
Note that we included the constructs form the HBM as these refer to individuals‟ 
cognitive representations or behavioural beliefs such as threat perception and evaluation of 
the costs and benefits of enacting the behaviour that may underpin more direct attitude 
assessments [14]. In order to minimise bias resulting from statistically dependent findings 
[18] global composite scores were coded wherever available and no more than two 
associations were extracted from a single study.  Where there were more data available, the 
later outcome i.e., that measured most distant to the attitude measure was extracted. When 
different values other than r were reported, the following effect size types were converted 
into r:  t,  F, X
2
 . 
2.3 Quality criteria 
Due to the problems of multiple testing, a global index of study quality was 
developed. The following criteria and coding were used to assess for each association the 
quality of the study reporting it: the sample size (<30 = 0, ≥30 and <100 = 1, ≥100 = 2), 
study  design (cross sectional = 0 and prospective = 1), the conceptual validity of the 
instrument used to measure attitude (confounded attitude measure = 0, „pure‟ attitude 
assessment = 1), validity of the adherence measure  (no established scale = 0, established 
scale = 1), reliability of adherence measure (self reported, by patient or observer = 0, 
combination of patient and observer self reports = 1, combination of objective and self 
reported measures = 2, objective measure = 3), internal reliability of attitude and adherence 
measures (internal consistency <.70 or non reported reliability = 0,  internal reliability  >.70 
= 1). When adherence was measured objectively rather than self reported internal reliability 
was assumed to be to adequate. Scores were summed across each item to create an overall 
quality score, ranging from 0 to 9 with higher scores indicating better study quality. Studies 
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were then allocated to one of three groups, i.e., low (0–3), medium (4–6) and high quality 
(7–9), a distinction used in other reviews [19]. 
2.4 Inter-rater reliability 
All articles were coded by two independent researchers.  An initial agreement rate of 
89% across all judgments was obtained and all disagreements were resolved through 
discussion. 
2.5 Analytic Strategy 
Hypotheses were examined in three analytic steps. First meta-analytic findings for 
the overall attitude effects were calculated.  Second, publication bias was assessed using 
Duval and Tweedie‟s trim and fill procedure [20].  Third, study quality was explored as a 
moderator of the attitude/adherence association. 
Consistent with accumulating evidence, heterogeneity in effect sizes was expected 
[21]. Thus, observed correlations were pooled and corrected for sampling error using a 
random effects model. The mean observed (r
+
) correlation and corresponding confidence 
intervals were also calculated. Heterogeneity between scores was assessed using  I
2
  and Q 
statistics.   The Q statistic reflects the total amount of variance in the meta analysis while the  
I
2
 value indexes the proportion of variance that is due to between-study differences and 
unlike the Q statistic, it is not sensitive to the number of studies considered.  I
2
  values range 
from 0 to 100% and it has been suggested that values of  of 25%, 50%, and 75% indicate 
low, moderate and higher heterogeneity, respectively [22]. 
 Publication of statistically significant results is more probable [23] which increase 
the likelihood of type 1 errors (and an over estimation of the mean effect size) in meta 
analysis. To examine this potential bias, we applied  Duval & Tweedie‟s  [20] “trim-and-fill” 
procedure which estimates the number of studies that may be missing due to publication 
bias, and then imputes these missing studies prior to re-calculating the attenuated effect size.  
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Plots of effect size against inverse standard errors around the mean effect size estimate were 
used in this analyses. For the moderation analyses, sub-group analysis was performed by 
grouping the associations by study quality and assessing heterogeneity between groups using 
the Qbetween statistic within a random effects model.  
Comprehensive Meta analysis, version 2.0 (Biostat; Englewood, New Jersey, USA) 
was used for all analyses 
 
3. Results 
 
At stage one the search strategy yielded a total of 641 papers.  After scanning 
abstracts and titles using the specified inclusion criteria 111 papers were identified as 
relevant and read in detail.  The substantial exclusions at this stage were due to a large 
number of studies that had not assessed both attitudes towards medication and adherence 
behaviours. 14 papers [ 9, 10, 24-35] of the 111 potentially relevant papers were found to 
meet all inclusion criteria and included in the review. The search process is summarized in 
Figure 1. 
The reported studies were conducted in Hong Kong, Spain, Denmark, the 
Netherlands, the United Kingdom, and the United States.  The percentage of patients with 
psychosis varied between 71% and 100%.  
 
3.1 Data Description 
A total of 19 independent correlations were analyzed.  Of these 13 (N =1911) were 
Pearson correlations (r) while 6 were Spearman Rank-order coefficients  (rs)  (N = 780).  Of 
the Pearson correlations, 8 were coded as poor in quality (N=1034) and 5 as moderate in 
quality (N=877).  There were no associations coded as good in quality. Of the Spearman 
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correlations,  3 associations were coded as poor in quality (N =519), 2 as moderate in quality 
(N =203)  and 1 as good in quality (N =58).    
Figures 2 and 3 present the meta-analytic results for the Pearson and Spearman 
correlations, respectively and include the study details, sample size (N),  each study r, the 
mean weighted (r
+
) and 95% confidence intervals (CIs),  
 
3.2 Overall  Attitude effect  for Pearson’s correlations 
 
 
The averaged corrected correlation between attitude and medication was r
+
 = 0.25, 
(CIs = 0.18, to  0.32), Q(12) 29.95, p <.05. This represents a small-to-medium effect size  
and as the confidence intervals did not include zero, the null hypothesis was rejected. All of 
the effects were positive in valence. The Q statistic, and an I
2
 statistic of 51.90% showed a 
moderate degree of heterogeneity in the effect size across the studies, which indicated the 
likelihood of moderators [36].   
 
3.3 Overall  Attitude effect for Spearman’s correlations 
 
The averaged corrected correlation between attitude and medication was r
+
 = 0.26, 
(CIs =0.12, to 0.38], Q(5) 15.35, p = .01. This represents a small-to-medium effect size 
(Cohen, 1987) and as the confidence intervals did not include zero, the null hypothesis was 
rejected. All of the effects were positive in valence. The Q statistic, and an I
2
 statistic of 
67.43.% showed a substantial degree of heterogeneity in the effect size across the studies, 
which indicated the likelihood of moderators [36].  
 
3.4 Publication Bias 
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For the overall analyses we found no evidence of publication bias.  A single missing 
effect was identified for  the Spearman correlations. However, adjusting for the missing 
study, did not significantly alter the mean effect size (r
+
= .23, CIs= 0.09, to 0.36)  
 
 
3.5 Moderator analysis 
 
For the Pearson correlations, sub-group analysis indicated that the between study 
heterogeneity was not due to study quality, Qbetween  = 1.11 (1), p =.26  (for studies coded as 
medium r
+
  =.29, CIs=.19 to 38; for studies coded as poor, r
+
 =.22, CIs =.13 to .30)  There 
were not enough studies using Spearman correlations to explore study quality as a 
moderator.  
 
4. Discussion 
 
We systematically reviewed and meta analysed the empirical evidence on attitudes 
towards medication adherence and mediation adherence behaviours among patients with 
psychoses.  A positive relationship of a small to moderate magnitude was observed.  Study 
quality as a moderator did not account for the significant heterogeneity between studies. 
The review has various limitations. Because of the small number of studies we were unable 
to conduct univariate moderator analysis which may have explained some of the 
heterogeneity between studies.  Nonetheless, a global index of study quality did not 
moderate the attitude/adherence combination across the relevant studies suggesting that 
theoretical moderators may-be operating.  For example, side-effect profiles may moderate 
the attitude/adherence association with more noxious medications reducing adherence.  It is 
also important to consider stage of illness (recent onset versus chronic),  patient‟s psychotic 
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state (active versus remission) in addition to a number of individual characteristics such as 
length of illness, substance abuse, gender, ethnicity, and social economic status. 
The remaining limitations reflect the methodological shortcomings of the included 
studies, only one of which met the defined criteria for a high quality study. Crucially, some 
of the measures designed to assess patient attitudes are poorly conceptualised making it 
difficult to establish the „pure‟ association between attitudes and adherence behaviour.  For 
example, the ROMI designed to assess patient attitudes, includes aspects of therapeutic 
alliance and self efficacy which although relevant, may be distinctive concepts to patient 
attitudes.  Relatedly, internal reliability coefficients were reported in 4 studies for attitudes 
and a single study for adherence.  Additionally, only one study included an objective 
measure of adherence, with the majority  relying on self reports from either the patient or 
persons providing care.   
The finding that attitudes are small to moderately positively related to adherence 
behaviour among patients with psychoses is consistent with the findings in other domains 
and  populations, both in direction and size [14]  indicating that the patient decision making 
process  is relevant to clinical outcomes among patients with severe mental illness.  Thus, 
despite the specific illness characteristics typically associated with psychoses (e.g., lack of 
insight) the relationship between attitudes and medication adherence is comparable to other 
populations without any mental illness. This finding substantiates recent qualitative reviews 
[5] and adds to these by providing mean effect size estimates and indexes of heterogeneity.  
Importantly, this result is consistent with the growing body of evidence indicating that 
subjective patient reports are predictive of important clinical outcomes among patients with 
psychoses [6].  Moreover, in contrast to correlates traditionally associated with adherence 
behaviours among patients with psychoses, (i.e., demographic and clinical characteristics) 
attitudes are potentially modifiable and therefore provide a promising target for intervention. 
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The finding that patient attitudes towards medication adherence are positively related 
to behavioural adherence is consistent with SCMs such as the TPB. The TPB proposes that 
attitudes predict behavioural intentions which reflect an individual‟s motivation to engage in 
the behaviour.  Following this, patient motivation is the presumed mechanism that accounts 
for adherence behaviours among patients with psychoses.  Nonetheless, the TPB also 
acknowledges that positive intentions to engage in a behaviour is not always enough and self 
regulatory factors influence the capacity to translate intentions into action.  Thus, self 
regulatory skills such as setting specific plants to implement goals may be needed 
Theoretical models are rarely tested in research on medication adherence among 
psychiatric populations.  This is limiting as theoretical models like the TPB not only specify 
the causal mechanism of behaviour change but facilitate the conceptualisation of distinct but 
closely related constructs [37]. For example, the TPB identifies normative beliefs, and 
perceptions of control as distinct antecedents of behavioural intention.   The current findings 
indicate that SCMs such as the TPB may be relevant to patients with psychoses although the 
measures may need to be adapted.  Models such as the TPB are often an attractive for 
researchers as additional constructs can be added when they explain  variation over and 
above those already specified in the model. Thus other constructs (e.g., therapeutic alliance) 
if found to be relevant could be included.  
  This review indicates that interventions targeting patient attitudes could be 
developed.  An example is the leaflet-like intervention [38]  that included persuasive
 
communication targeting the formation of positive attitudes by highlighting the advantages 
of
 
drinking within daily limits (e.g., fewer headaches
 
and hangovers and lower risk of liver 
disease).  Similar interventions could be developed and evaluated in the context of 
medication adherence and could have direct implications for healthcare policy and clinical 
practice.  The development of interventions is important, because, unlike correlation studies, 
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where only associations are tested, causal statements about the direction of the association 
can be made in addition to assessments of clinical relevance.  A recently developed 
taxonomy of behaviour change techniques [37]  could facilitate the selection of appropriate 
technique(s) for targeting attitude change and subsequent medication adherence. 
This review underlines the need for methodologically more rigorous research and 
points to at least three requirements for future research in the area.  First, attitude and 
adherence should be assessed with accurate instruments that have been shown to be valid 
measures among patients with psychosis. Second, research should consider the role of 
attitudes after consideration of other relevant constructs (e.g., therapeutic relationship), in 
addition to potential mediating and moderating factors using a theoretical framework such as 
the TPB.  Third, interventions designed to target and improve patient attitudes towards 
medication adherence should be developed and evaluated.  
Medication adherence is a complex issue particularly among patients with psychoses.  
The evidence reviewed here identifies patient attitudes as central to adherence. Specifically, 
among patients with psychoses, subjective evaluations of medication adherence were shown 
to be positively related to adherence behaviours. Rational decision making models such as 
the TPB could therefore be tested empirically among patients with psychoses. 
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Table 1.   
Study Details for the Pearson Correlations 
Author(s) and year Country  Sample size 
and % with 
psychosis  
Attitude Measure(s) Study design (CR= 
cross sectional, 
PRO=prospective) 
and length of time 
to outcome  
Adherence measure(s)  
 
 
Effect size 
estimate r 
and N 
Reliability of 
attitude 
measure(s) 
Reliability of 
adherence 
measure(s) 
Agarwal et al., 1998 UK 78 
(100%) 
DAI CR Combination of patient and observer rated 
compliance based on Lin et al., 1979. 
r = .23, 
n=76 
Not reported Not reported 
Donohoe et al., 2001 UK  32 
(100%) 
DAI CR Observer rated using a structured clinical 
interview  (Adams and Howe, 1993).   
r=.62,  
n=32 
Not reported Not reported 
Haan et al., 2007 Netherlands 119 
(100%) 
ROMI , global scale PRO 
5 years 
Observer rated compliance, developed by 
authors.  
r=.13, 
n=97 
Not reported Not reported 
Kamali et al., 2001 UK 87 
(100%) 
DAI CR Observer rated using a structured clinical 
interview (Adam and Howe, 1993)   
r=18,  
n=66 
 
Not reported Not reported 
Kapelowics et al., 
2007. 
America 
(Mexican-
American 
population) 
155  
(100%) 
TPB, Attitude construct CR Treatment compliance interview (TCI;  
Weiden et al., 1995)  (Patient,  relative and 
treatment provider versions used). 
r =.37, 
n=155 
 
α=.91 Not reported 
Kelly et al.,  
1987 
USA 107 
(72%) 
 
HBM, Barriers construct CR Self reported compliance (9 items) 
developed by authors.  
r=.32r, 
n=107 
α=.98 
 
α=.90 
 
HBM, Benefits construct r=.20, 
n=107 
α=.80 
 
Mutsatsa et al., 2003 UK 101 
(100%) 
ROMI, compliance items. PRO 
Maximum 3 weeks. 
Observer rated compliance, using the 
compliance rating scale (CRS;  Hayward et 
al., 1995) 
r =.04,  
n=101 
Not reported Not reported 
ROMI, non-compliance 
items 
r =.29r, 
n=101 
Not reported 
Tsang et al., 2009. Hong Kong 86 
(100%) 
ROMI, compliance items. CR 
 
 
Observer rated compliance using the Kemp 
Compliance scale (KCS;  Kemp et al., 
1996).  
r=.30, 
n=86 
 
Not reported Single item 
ROMI, non-compliance 
items. 
r =.33r, 
n=86 
Not reported 
 Quach et al. 2009. Denmark 432 
(100%) 
ROMI, compliance items. PRO 
2 years 
Observer rated, based on structured 
interview with clients, information from 
primary care-givers as well as examination 
of patient’s medical records. 
r=.29c, 
n=432 
Not reported Not reported 
 
 
 
   ROMI, non-compliance 
items. 
  r=.13c, 
n=432 
Not reported  
Table
DAI=drugs attitude inventory, TPB=theory of planned behaviour, , AMQ= attitudes to medication questionnaire, DBS=Drug behaviour scale, MARS=medication attitude 
rating scale,  
r 
= reversed scored, 
c
= converted into r.
 
 
Table 2.   
Study Details for the Spearman Correlations 
 
Author(s) and 
year 
Country  Sample 
size and 
% with 
psychosis  
Attitude Measure(s) Study design 
(CR= cross 
sectional, 
PRO=prospective) 
and length of time 
to outcome  
Adherence measure(s)  
 
 
Effect 
size 
estimate r 
and N 
Reliability 
of attitude 
measure(s) 
Reliability 
of adherence 
measure(s) 
Cabeza et al., 
2000. 
Spain 60 
(100%) 
DAI CR Observer rated based on deviation 
from prescribed medication taking 
and unjustified missed 
appointments. 
r=.46,  
n=60 
 
Not reported Not reported 
Dolder et al., 
2004. 
USA 58 
(100%) 
DAI CR Refill compliance r=.07,  
n=58 
Not reported Not reported 
Failko et al., 
2008. 
UK 277 
(100%) 
MARS, 
Attitude subscale 
CR Observer rated compliance using 
the compliance item of the 
Engagement Measure (Hall et al., 
2001) 
r=.10,  
n=277 
α=..44 Single item 
Hayward et al., 
1995. 
UK 21 
(71%) 
AMQ 
 
PRO (variable, 
one–two months 
after discharge). 
Observer rated by doctors 
responsible for the patients care. 
r=.58, 
n=21 
 
Not reported Not reported 
Kennedy et al., 
2003. 
UK 182 
(100%) 
TPB, Attitude 
construct 
CR The Kemp adherence scale, 
(KCS;  Kemp et al., 1996) 
Observer rated (key worker) 
r=.20,  
n=182 
α=..7 Single item 
Drug behaviour scale (DBS; 
Kennedy et al., 2003). self 
reported.  
r=.32r, 
n=182 
 
α=..7 Not reported 
Table
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Search process of the literature 
 
 
 
 
Potentially relevant citations 
identified in PsycINFO. 
PsycARTICLES, and Medline 
between 1980-2010 (n =641) 
Full studies retrieved for more 
detailed evaluation: (n = 111) 
 
Studies included in the analysis: 
(n = 14) 
Citations excluded: (n = 530) 
 no standardised measure 
of attitude and/or 
adherence 
 non-English language 
articles 
 Non- diagnostic 
psychoses samples 
 
 
 Studies excluded after full text 
retrieval (n = 97) 
 no standardised 
measurement of attitude 
and/or adherence 
 < 70% of sample  
diagnosed with 
psychoses 
 Relevant data not 
reported and unavailable 
from the author 
 
 
 
Independent correlations (k) 
included in the analysis (k =19) 
 For Pearson’s 
correlations, k=13  
 For Spearman’s 
correlations, k=6 
 
 
 
Figure
 Note : 
a 
= benefits;
b
 = non-compliance items, 
 
Fig. 2    Forest plot of the Pearson correlations (with 95% confidence intervals) between 
attitude and medication adherence. 
 
 
 
 
 
 
 
 
 
 
 
Study and sample size Correlation and 95% CI 
 
Agarwal et al., 1998 76 
Donohoe et al., 2001 32 
Haan et al., 2007 97 
Kamali et al., 2001 66 
Kapelowics et al.,2007 155 
Kelly et al., 1987 107 
Kelly et al., 1987a 107 
Mutsatsa et al., 2003 101 
Mutsatsa et al., 2003b 101 
Quach et al., 2009 432 
Quach et al., 2009b 432 
Tsang et al, 2009b 119 
Tsang et al., 2009 86 
-1.00 -0.50 0.00 0.50 1.00 
Pearson’s r  
 
Figure
 Fig.3.  Forest plot of Spearman correlations (with 95% confidence intervals) between attitude 
and medication adherence 
 
Study and sample size Correlation and 95% CI 
 
 
Cabeza et al., 2000 60 
Dolder et al., 2004 58 
Failko et al., 2008 277 
Hayward et al., 1995 21 
Kennedy et al., 2003 182 
Kennedy et al., 2003
a 182 
-1.00 -0.50 0.00 0.50 1.00 
Spearman’s r 
 Note.
a
 = drug behaviour scale items 
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